Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €50.04 EUR
Change Today -1.21 / -2.35%
Volume 0.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 10:39 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (8AK) Snapshot

Open
€50.44
Previous Close
€51.25
Day High
€51.88
Day Low
€50.04
52 Week High
03/5/15 - €67.90
52 Week Low
10/13/14 - €30.36
Market Cap
7.4B
Average Volume 10 Days
67.0
EPS TTM
€-0.64
Shares Outstanding
148.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALKERMES PLC (8AK)

alkermes plc (8AK) Related Businessweek News

View More BusinessWeek News

alkermes plc (8AK) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.

1,300 Employees
Last Reported Date: 02/24/15
Founded in 1987

alkermes plc (8AK) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $854.7K
President
Total Annual Compensation: $630.6K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $468.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $468.1K
Chief Compliance Officer, Chief Legal Officer...
Total Annual Compensation: $459.4K
Compensation as of Fiscal Year 2014.

alkermes plc (8AK) Key Developments

Alkermes plc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Full Year of 2015

Alkermes plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s adjusted net income totaled $9.2 million or $0.06 per basic and diluted share, down from $16.2 million or $0.11 per basic and diluted share a year earlier. On a GAAP-basis, the net loss widened to $30.7 million or $0.21 per basic and diluted share from $24.4 million or $0.17 per basic and diluted share in the year-ago period. Revenues totaled $161.214 million, up 23.8% year-on-year compared to $130.212 million a year ago. Loss before income taxes was $30.147 million compared to $20.588 million a year ago. Capital expenditures were $10.710 million compared to $5.685 million a year ago. Free cash flow was $1.553 million compared to $10.466 million a year ago. For fiscal 2015, the company continues to expect a non-GAAP net loss of $0.37 to $0.50 per share on revenues of $600 million to $630 million.

Alkermes plc to Report Q1, 2015 Results on Apr 30, 2015

Alkermes plc announced that they will report Q1, 2015 results at 8:30 AM, US Eastern Standard Time on Apr 30, 2015

Alkermes plc, Q1 2015 Earnings Call, Apr 30, 2015

Alkermes plc, Q1 2015 Earnings Call, Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €50.04 EUR -1.21

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.157.60 CHF -1.40
Depomed Inc $23.68 USD -0.213
Emergent Biosolutions Inc $30.93 USD -0.15
Jazz Pharmaceuticals PLC $179.02 USD -4.21
Pacira Pharmaceuticals Inc/DE $66.12 USD -0.75
View Industry Companies
 

Industry Analysis

8AK

Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.5x
Price/Book 6.2x
Price/Cash Flow 359.0x
TEV/Sales 11.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.